Autori: Andric Zoran G
| Naslov | Expression pattern of circulating long non-coding RNA GAS5 as a novel biomarker in non-small cell lung cancer patients (Article) |
| Autori | Vesovic Natasa V Tosic Natasa M Karan-Djurasevic Teodora Z Andric Zoran G Zdravkovic Darko D Pavlovic Sonja T Jovanovic Dragana D |
| Info | ARCHIVES OF MEDICAL SCIENCE, (2026), vol. 22 br. 1, str. 469-475 |
| Projekat | Ministry of Ed-ucation, Science and Technological Development, Republic of Serbia [III 41004] |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer (Article) |
| Autori | Andric Zoran G ... (broj koautora 16) |
| Info | CANCER TREATMENT AND RESEARCH COMMUNICATIONS, (2025), vol. 44 br. , str. - |
| Projekat | Celltrion, Inc. (Incheon, Republic of Korea) |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON) (Article) |
| Autori | Tobias Joshua ... Andric Zoran G ... Nikolic Ivan V Petrovic Zoran ... (broj koautora 17) |
| Info | CLINICAL CANCER RESEARCH, (2024), vol. 30 br. 18, str. 4044-4054 |
| Projekat | Imugene Ltd. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study (Article) |
| Autori | Reck Martin ... Andric Zoran G ... (broj koautora 24) |
| Info | LUNG CANCER, (2024), vol. 196 br. , str. - |
| Projekat | F. Hoffmann-La Roche Ltd. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer (Article) |
| Autori | Spigel David R ... Stojanovic Goran ... Andric Zoran G ... (broj koautora 17) |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2024), vol. 42 br. 19, str. - |
| Projekat | Ipsen |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial (Article) |
| Autori | Reck Martin ... Andric Zoran G ... (broj koautora 18) |
| Info | JOURNAL OF THORACIC ONCOLOGY, (2024), vol. 19 br. 2, str. 297-313 |
| Projekat | Healthcare business of Merck KGaA, Darmstadt, Germany; Pfizer |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: |
| Naslov | Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC (Article) |
| Autori | Andric Zoran G ... Stojanovic Goran Petrovic Marina D ... (broj koautora 21) |
| Info | JTO CLINICAL AND RESEARCH REPORTS, (2023), vol. 4 br. 2, str. - |
| Projekat | Healthcare business of Merck KGaA, Darmstadt, Germany; Merck KGaA, Darmstadt, Germany; Pfizer |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study (Article) |
| Autori | Leal Ticiana A ... Andric Zoran G ... (broj koautora 25) |
| Info | LANCET ONCOLOGY, (2023), vol. 24 br. 9, str. 1002-1017 |
| Projekat | Novocure |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial (Article) |
| Autori | Verschraegen Claire Andric Zoran G Moiseenko Fedor Makharadze Tamta Shevnya Sergii Oleksiienko Alona Ruiz Eduardo Yanez Kim SungHyun Ahn KeumYoung Park TaeHong Park Sijin Ju Hana Ohe Yuichiro |
| Info | BIODRUGS, (2022), vol. 36 br. 6, str. 749-760 |
| Projekat | Celltrion, Inc. (Incheon, Republic of Korea) |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
| Naslov | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2 (Article) |
| Autori | Goel Shom Tan Antoinette R Rugo Hope S Aftimos Philippe Andric Zoran G Beelen Andrew Paul Zhang Jingshan Yi John S Malik Rajesh K O'Shaughnessy Joyce |
| Info | FUTURE ONCOLOGY, (2022), vol. 18 br. 33, str. 3701-3711 |
| Projekat | G1 Therapeutics; Eli Lilly; Merck; Pfizer; AstraZeneca; Ayala; Boehringer Ingelheim; Daiichi; Gilead; Lilly; Macrogenics; Novartis; OBI; Odonate; Polyphor; Roche; Seattle Genetics; Sermonix |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
